共 33 条
[1]
Gettinger S(2018)Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study J Clin Oncol 36 1675-1684
[2]
Horn L(2018)Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer JAMA Oncol 4 374-378
[3]
Jackman D(2018)Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC Cancer Immunol Res 6 1093-1099
[4]
Haratani K(2018)Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases Cancer Chemotherapy Pharmacol 81 1105-1109
[5]
Hayashi H(2019)Increased efficacy of ramucirumab plus docetaxel after nivolumab failure against previously treated non-small cell lung cancer Thoracic Cancer 10 775-781
[6]
Chiba Y(2019)Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab Thoracic Cancer 10 992-1000
[7]
Santini FC(2009)New response evaluation criteria in solid tumour: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[8]
Andrew HR(2018)Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Lancet Oncol 19 1480-1492
[9]
Plodkowski J(2018)Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience Invest New Drugs 36 638-646
[10]
Fujita K(2017)Reinduction of PD-1-inhibitor therapy: first experience in eight patients with metastatic melanoma Melanoma Res 27 321-325